Social media

CRAs are at the centre of clinical trial evolution. Risk-based monitoring, intelligent oversight tools and AI are changing how trials are managed. ICON explores what this means for the future in Pharma Times: https://ow....

In the age of technology, site-based assessments are no longer the only ways of collecting valuable data to demonstrate treatment efficacy. The advent and growing acceptance of DHTs, which collect data from patients du...

Site activation delays cost trials time and trust. ICON’s new whitepaper shows how human-centred strategies accelerate startup and improve site satisfaction. Download now: https://ow.ly/qU2y50XB71b

Delays erode site confidence. Learn how ICON helps sponsors maintain momentum and prevent site burnout. Explore the insights: https://ow.ly/3w8u50XB70W

What separates winners from laggards in drug development is recognising the macro trends in the regulatory environment at the highest level of the company and formulating strategies to deliver; - Agility in regulatory st...

What separates winners from laggards in drug development is recognising the macro trends in the regulatory environment at the highest level of the company and formulating strategies to deliver; - Agility in regulatory st...

Recognising ICON’s Environmental, Social & Governance (ESG) commitment through our ICON Cares programme, we are honoured to be named one of the world’s best by TIME/ Statista. This list ranks the world’s 500 most sustain...

Recognising ICON’s Environmental, Social & Governance (ESG) commitment through our ICON Cares programme, we are honoured to be named one of the world’s best by TIME/ Statista. This list ranks the world’s 500 most susta...

For the third and final blog in our series, we discuss ISO 10993-1 in the context of risk estimation. This blog looks at the upcoming revision of ISO 10993-1, which has sparked debate but now is in its final draft stag...

For the third and final article in our series, ICON’s regulatory expert Jeremy Tinkler discusses ISO 10993-1 in the context of risk estimation. This article looks at the upcoming revision of ISO 10993-1, which has spar...

From wearables to ePROs, trials are data-rich and decentralised. CRAs must evolve. ICON’s Helen Yeardley explores this evolution in Applied Clinical Trials. https://ow.ly/TNaS50XB6Sc

From wearables to ePROs, trials are data-rich and decentralised. CRAs must evolve. ICON’s Helen Yeardley explores this evolution in Applied Clinical Trials. https://ow.ly/TNaS50XB6Sc